The Stem Cell Podcast

Ep. 301: “Cell Fate Decisions in Cancer” Featuring Dr. Mark Hatley

Aug 5, 2025
Guest
Mark Hatley
Dr. Mark Hatley, a leading researcher in pediatric oncology from St. Jude Children’s Research Hospital, dives deep into the genetic underpinnings of childhood cancers such as rhabdomyosarcoma. He unpacks how the PAX3-FOXO1 and DICER1 genes contribute to tumor formation. The discussion highlights the critical shift from animal models to human systems in cancer research, providing fresh insights into potential treatments. Hatley emphasizes the importance of understanding developmental biology to uncover innovative strategies for combating pediatric cancer.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Hypoimmune Donor Islets Function Without Drugs

  • Hypoimmune gene-edited allogeneic islet cells survived without immunosuppression in a human recipient for at least 12 weeks.
  • C-peptide measurements confirmed functional, glucose-responsive insulin secretion from the graft.
INSIGHT

Innate Immunity Limits Early Xenograft Function

  • Xenotransplanted pig organs show early function but reveal innate immune and thrombotic challenges on transcriptomic inspection.
  • Identifying monocyte and T-cell phases suggests targeted interventions could improve xenograft outcomes.
INSIGHT

Chemical Reprogramming From A Drop Of Blood

  • Chemical reprogramming now converts cord and adult peripheral blood into hiCiPS efficiently, even from a finger‑prick drop.
  • This enables easier, less invasive sourcing of iPSCs for research and therapies.
Get the Snipd Podcast app to discover more snips from this episode
Get the app